Sign in
Taking people in United StatesNo phase

Cleaner Vac device for blood clots in the upper leg veins

Watches how a clot-removal device works in adults with leg deep vein thrombosis.

Key facts

Who runs it
Argon Medical Devices
Where
Edgewood, Fort Lauderdale, Indianapolis, and Plano, United StatesSee the 4 sites
Trial code
Registry title
Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking
Status
Recruiting
People taking part
185 people, planned
Started
4 Feb 2026
Expected to end
Jun 2029
Type of study
Observational
Treatments tested
  • Aspiration thrombectomy system
Record updated
20 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a recent blood clot in a deep vein of the leg or pelvis. They will be treated first with the Cleaner Vac® Thrombectomy System, a device that sucks out the clot.

Age
18 years or older.
Sex
All sexes.
Disease stage
Deep vein thrombosis (DVT) in one or both legs. It must involve the femoral-popliteal, common femoral or iliac vein, or the inferior vena cava (IVC). Symptoms started within 6 weeks of enrollment. Imaging confirmed the clot within 14 days of the procedure.
Earlier treatment
The Cleaner Vac® device must be the first treatment for the clot. People cannot join if clot-dissolving drugs (thrombolytics) were used on the same vein in the previous 14 days.

Main reasons for not taking part

  • Cannot take blood thinners, or cannot have iodine contrast dye even with medicine given beforehand.
  • Pregnancy.
  • Severe kidney problems (GFR < 30 ml/min) without dialysis. People already on dialysis can join.
  • Intermediate-high or high-risk clot in the lung (pulmonary embolism), or a known patent foramen ovale (PFO), a small opening between the heart's upper chambers.
  • Life expectancy less than 1 year due to advanced cancer, or long-term inability to walk.

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Participants must meet all the following criteria to be eligible for the study:
  • At least 18 years of age at the time of consent
  • Undergo frontline (primary) treatment with Cleaner Vac® Thrombectomy System in the peripheral venous vasculature and have at least one component introduced into the body
  • Written informed consent obtained through the IRB-approved ICF; For the DVT cohort, participants must meet all criteria above and below to be eligible for the study:
  • Present with unilateral or bilateral lower extremity DVT involving at least one of the following veins:; Femoral-popliteal vein; Common femoral vein; Iliac vein; Inferior Vena Cava (IVC)
  • DVT diagnosis confirmed by imaging within 14 days of the index procedure
  • Symptomatic DVT with onset within 6 weeks of enrollment

Who cannot take part

  • Treatment of target venous segment with thrombolytics within previous 14 days of the index procedure
  • Current enrollment in another investigational device or drug study that may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational studies
  • Life expectancy less than 1 year due to advanced malignancy, as determined by the investigator at the time of enrollment
  • Known coagulation disorders both acquired (Heparin Induced Thrombocytopenia, etc.) or genetic (e.g., Factor V Leiden, etc.), thrombophilia, or hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period
  • Known history of a Patent Foramen Ovale (PFO)
  • Patients with intermediate-high risk or high-risk pulmonary embolism (PE) defined as follows:; High-risk PE: Presence of hemodynamic instability, including cardiac arrest, obstructive shock (systolic blood pressure <90 mmHg or need for vasopressors with signs of end-organ hypoperfusion), or persistent hypotension (systolic BP <90 mmHg or a drop ≥40 mmHg for >15 minutes not due to other causes); Intermediate-high-risk PE: Hemodynamically stable patients with both right ventricular (RV) dysfunction (on echocardiography or CT) and elevated cardiac biomarkers (e.g., troponin)
  • Hemoglobin < 8.0 g/dL, INR > 2.0 before warfarin was started, or platelets < 50,000/µl which cannot be corrected prior to enrollment
  • Severe renal impairment (estimated GFR < 30 ml/min) in patients who are not yet on dialysis. Patients with GFR <30 ml/min who are already on dialysis can be enrolled
  • Subjects will be excluded from the study if any of the following criteria are met:
  • Contraindication to systemic or therapeutic doses of anticoagulants
  • Contraindication to iodinated contrast that cannot be adequately premedicated
  • Patients that are pregnant
  • Known congenital anatomic anomalies of the inferior vena cava (IVC) or iliac veins
  • Complete infrarenal IVC occlusion
  • Chronic non-ambulatory status

Where in United States

  • St. Elizabeth Healthcare - EdgewoodEdgewood, United StatesContact: Alisha HartmannTaking people
  • Janna, LLCFort Lauderdale, United StatesContact: Vicky RodriguezTaking people
  • Indiana University HealthIndianapolis, United StatesContact: Siji MathachanTaking people
  • Baylor Scott & White The Heart Hospital - PlanoPlano, United StatesContact: Erika V Ortiz, BATaking people

About the trial

What the trial wants to find out

The primary objective of this clinical investigation is to evaluate the safety and effectiveness of the Cleaner Vac® Thrombectomy System for the treatment of thrombus in patients with lower extremity proximal deep vein thrombosis (DVT). This prospective, multi-center, open-label study will assess clinical outcomes, device performance, and procedural success in a single DVT study cohort.

The group in the trial

  • DVT Subgroup

    This is a defined cohort focused on patients with lower extremity proximal deep vein thrombosis (DVT) who will undergo treatment with Cleaner Vac® Thrombectomy System. Participants will complete required follow-up at discharge and at 1, 6, 12, and 24 months.

    Treatment: Aspiration thrombectomy system

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Prospective, Multi-Center, Open-Label Clinical Investigation of the Cleaner Vac® Thrombectomy System for Treatment of Lower Extremity Proximal Deep Vein Thrombosis (DVT)
Plain-language title
Cleaner Vac device for blood clots in the upper leg veinsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
20 October 2026